<DOC>
	<DOCNO>NCT01529112</DOCNO>
	<brief_summary>The purpose study compare overall survival patient receive E7080 + Best Supportive Care ( BSC ) receive placebo + Best Supportive Care .</brief_summary>
	<brief_title>A Study Comparing Combination Best Supportive Care Plus E7080 Versus Best Supportive Care Alone , Patients With Advanced Lung Cancer Lung Cancer That Has Spread , Who Have Been Previously Treated , Unsuccessfully , With Least 2 Different Treatments</brief_title>
	<detailed_description>This double-blind , placebo-controlled , multicenter , randomize Phase II study consist 2-arm design , compare E7080 + BSC ( Arm 1 ) placebo + BSC ( Arm 2 ) . Participants randomize ratio 2:1 receive either E7080 placebo blind manner .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Lenvatinib</mesh_term>
	<criteria>Inclusion Criteria 1 . Age great equal 18 year ; 2 . Participants histologically cytologically confirm nonsquamous NSCLC locally advance metastatic disease base Tumor , Node , Metastasis ( TNM ) stag accord American Joint Committee Cancer ( AJCC ) Cancer Staging Manual , Seventh Edition , fail least two line systemic anticancer therapy advance metastatic NSCLC ( include adjuvant chemotherapy ) . In country erlotinib approve marketed treatment NSCLC , participant must receive erlotinib treatment ( gefitinib participant outside US ) NSCLC know EGFRactivating mutation . Participants unknown EGFR status receive prior erlotinib ( gefitinib ) test EGFRactivating mutation prior study entry . In country crizotinib approve market , participant must receive crizotinib treatment NSCLC ALKpositive . Participants ALK positive NCSLC participant KRAS mutation require prior treatment erlotinib gefitinib 3 . Participants must least 1 site measurable disease Response Evaluation Criteria Solid Tumors version 1.1 ( RECIST v.1.1 ) ; 4 . ECOG PS 0 2 ; 5 . Participants must adequate renal function evidence serum creatinine less equal 1.5 x upper limit normal ( ULN ) calculate creatinine clearance great equal 30 mL/min per Cockcroft Gault formula ; 6 . Blood pressure must wellcontrolled ( less equal to140/90 mm Hg Screening ) without antihypertensive medication . Participants must history hypertensive crisis hypertensive encephalopathy ; 7 . Participants must adequate bone marrow function evidence absolute neutrophil count ( ANC ) great equal 1.5 x 109/L , hemoglobin great equal 9.0 g/dL , platelet count great equal 100 x 109/L ; 8 . Participants must adequate liver function evidence bilirubin less equal 1.5 time ULN , alkaline phosphatase , alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) less equal 3 x ULN ( case liver metastasis , less equal 5 x ULN ) . 9 . Participants must adequate coagulation system function define prothrombin time/International normalize ratio ( INR ) less equal 1.5 x ULN . 10 . Male female participant childproducing potential must agree use double barrier contraception , oral contraceptive , avoidance pregnancy measure study 90 day last day treatment ; 11 . Females childbearing potential must negative serum pregnancy test ; 12 . Females may breastfeed ; 13 . Ability understand willingness sign write informed consent . Exclusion Criteria 1 . Prior therapy E7080 small molecule vascular endothelial growth factor inhibitor ; 2 . Presence brain metastasis , unless participant received adequate treatment least 4 week prior randomization , stable , asymptomatic , steroid least 4 week prior randomization ; 3 . Meningeal carcinomatosis ; 4 . Received chemotherapy , target therapy , radiotherapy , surgery , immunotherapy within 21 day prior commence study treatment recover treatmentrelated toxicity Grade le equal 2 , except alopecia ; 5 . Received treatment another investigational agent within 30 day prior commence study treatment participant recover side effect investigational drug Grade le equal 2 , except alopecia ; 6 . Participants proteinuria great 1+ urine dipstick test undergo 24hour urine collection quantitative assessment proteinuria . Participants 24hour urine protein great equal 1 g/24 hour ineligible ; 7 . Serious nonhealing wound , ulcer , bone fracture , undergone major surgical procedure , open biopsy , significant traumatic injury within 28 day prior commence study treatment . 8 . Major surgery schedule project course study ; 9 . History bleed diathesis coagulopathy ; 10 . Active hemoptysis ( define bright red blood half teaspoon ) within 30 day prior study entry ; 11 . Refractory nausea vomiting , malabsorption , significant bowel resection , medical condition would preclude adequate absorption result inability take oral medication ; 12 . Other malignancy within 3 year randomization , exception adequately treat carcinoma situ cervix nonmelanoma skin cancer , subsequent evidence recurrence and/or malignancy diagnose stage definitive therapy result near certain cure . 13 . Significant cardiovascular impairment ( history congestive heart failure New York Heart Association [ NYHA ] Class great II , unstable angina myocardial infarction within past 6 month , serious cardiac arrhythmia ) ; 14 . Any history cerebral vascular accident ( CVA ) , transient ischemic attack ( TIA ) , Grade great equal 2 peripheral vascular disease unless evidence active disease least 6 month prior randomization ; 15 . History abdominal fistula , gastrointestinal perforation , intraabdominal abscess within 6 month prior enrollment ; 16 . Participants organ allograft require immunosuppression ; 17 . Known positive human immunodeficiency virus ( HIV ) , know hepatitis B surface antigen , hepatitis C positive ; 18 . Hypersensitivity E7080 excipients ; 19 . Any history concomitant medical condition , opinion Investigator , would compromise participant 's ability safely complete study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Locally Advanced</keyword>
	<keyword>Metastatic Non-Squamous Non-Small Cell Lung Cancer</keyword>
</DOC>